Professional Documents
Culture Documents
非酒精性脂肪性肝病与相关代谢紊乱诊疗
非酒精性脂肪性肝病与相关代谢紊乱诊疗
7 549
•指南与共识•
非酒精性脂肪性肝病与相关代谢紊乱诊疗
共识( 第二版)
中华医学会内分泌学分会
小檗碱可使患者肝脏脂肪含量比单纯生活方式干预组 [7] Williamson RMꎬ Price JFꎬ Glancy Sꎬ et al. Prevalence of and risk
factors for hepatic steatosis and nonalcoholic fatty liver disease in people
降低 52%( P = 0.008) ꎮ 同时ꎬ降低患者的体重ꎬ改善血 with type 2 diabetes: the Edinburgh Type 2 Diabetes Study [ J ] .
脂谱、增加胰岛素敏感性ꎬ并且具有良好的耐受性 [66] ꎮ Diabetes Careꎬ 2011ꎬ34(5) :1139 ̄1144. DOI: 10.2337 / dc10 ̄2229.
目前ꎬ小檗碱治疗前后经病理评估 NASH 的随机双盲 [8] Targher Gꎬ Bertolini Lꎬ Padovani Rꎬ et al. Prevalence of nonalcoholic
fatty liver disease and its association with cardiovascular disease among
对 照 临 床 研 究 正 在 进 行 中 ( ClinicalTrials. gov ID: type 2 diabetic patients [ J ] . Diabetes Careꎬ 2007ꎬ 30 ( 5 ) : 1212 ̄
NCT03198572) ꎮ 1218. DOI: 10.2337 / dc06 ̄2247.
中华内分泌代谢杂志 2018 年 7 月第 34 卷第 7 期 Chin J Endocrinol Metabꎬ July 2018ꎬ Vol. 34ꎬ No. 7 553
[9] Petit JMꎬ Guiu Bꎬ Terriat Bꎬ et al. Nonalcoholic fatty liver is not [25] Bhala Nꎬ Angulo Pꎬ van der Poorten Dꎬ et al. The natural history of
associated with carotid intima ̄media thickness in type 2 diabetic patients nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an
[ J] . J Clin Endocrinol Metabꎬ 2009ꎬ 94 ( 10 ) : 4103 ̄4106. DOI: international collaborative study[ J] . Hepatologyꎬ 2011ꎬ54( 4) :1208 ̄
10.1210 / jc.2009 ̄0541. 1216. DOI: 10.1002 / hep.24491.
[10] Bril Fꎬ Cusi K. Nonalcoholic fatty liver disease: the new complication of [26] Vozarova Bꎬ Stefan Nꎬ Lindsay RSꎬ et al. High alanine aminotransferase
type 2 diabetes mellitus[ J] . Endocrinol Metab Clin North Amꎬ 2016ꎬ is associated with decreased hepatic insulin sensitivity and predicts the
45(4) :765 ̄781. DOI: 10.1016 / j.ecl.2016.06.005. development of type 2 diabetes [ J] . Diabetesꎬ 2002ꎬ 51 ( 6 ) : 1889 ̄
[11] Leite NCꎬ Villela ̄Nogueira CAꎬ Pannain VLꎬ et al. Histopathological 1895.
stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences [27] Adams LAꎬ Waters ORꎬ Knuiman MWꎬ et al. NAFLD as a risk factor for
and correlated factors [ J] . Liver Intꎬ 2011ꎬ 31 ( 5 ) : 700 ̄706. DOI: the development of diabetes and the metabolic syndrome: an eleven ̄year
10.1111 / j.1478 ̄3231.2011.02482.x. follow ̄up study [ J] . Am J Gastroenterolꎬ 2009ꎬ 104 ( 4 ) : 861 ̄867.
[12] Fracanzani ALꎬ Valenti Lꎬ Bugianesi Eꎬ et al. Risk of severe liver DOI: 10.1038 / ajg.2009.67.
disease in nonalcoholic fatty liver disease with normal aminotransferase [28] Ballestri Sꎬ Zona Sꎬ Targher Gꎬ et al. Nonalcoholic fatty liver disease is
levels: a role for insulin resistance and diabetes[ J] . Hepatologyꎬ 2008ꎬ associated with an almost twofold increased risk of incident type 2
48(3) :792 ̄798. DOI: 10.1002 / hep.22429. diabetes and metabolic syndrome. Evidence from a systematic review and
[13] Kwok Rꎬ Choi KCꎬ Wong GLꎬ et al. Screening diabetic patients for non ̄ meta ̄analysis[ J] . J Gastroenterol Hepatolꎬ 2016ꎬ 31 ( 5) : 936 ̄944.
alcoholic fatty liver disease with controlled attenuation parameter and DOI: 10.1111 / jgh.13264.
liver stiffness measurements: a prospective cohort study [ J ] . Gutꎬ [29] 中华医学会内分泌学分会肝病与代谢学组( 筹) . 中华医学会内
2016ꎬ65(8) :1359 ̄1368. DOI: 10.1136 / gutjnl ̄2015 ̄309265. 分泌学分会“ 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识”
[14] Koehler EMꎬ Plompen EPꎬ Schouten JNꎬ et al. Presence of diabetes [ J] . 中华内分泌代谢杂志ꎬ 2010ꎬ26( 7) :531 ̄534. DOI: 10.3760 /
mellitus and steatosis is associated with liver stiffness in a general cma.j.issn.1000 ̄6699.2010.07.002.
population: the Rotterdam Study[ J] . Hepatologyꎬ 2016ꎬ63( 1) :138 ̄ [30] 中华医学会肝病学分会脂肪肝和酒精性肝病学组ꎬ 中国医师协
147. DOI: 10.1002 / hep.27981. 会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南( 2018
[15] 刘蒙ꎬ 颜红梅ꎬ 高鑫ꎬ 等. 非酒精性脂肪肝病患者中肝酶与代谢综 年更新 版) [ J] . 实 用 肝 脏 病 杂 志ꎬ 2018ꎬ21 ( 2) :177 ̄186. DOI:
合征的关 系 [ J] . 中 华 医 学 杂 志ꎬ 2007ꎬ 87 ( 4 ) : 253 ̄255. DOI: 10.3969 / j.issn.1672 ̄5069.2018.02.007.
10.3760 / j:issn:0376 ̄2491.2007.04.009. [31] Haberfellner EMꎬ Honsig T. Nonalcoholic steatohepatitis: a possible
[16] 张林杉ꎬ 卞华ꎬ 颜红梅ꎬ 等. 2 型糖尿病患者肝脏脂肪含量与肝病 side effect of atypical antipsychotics[ J] . J Clin Psychiatryꎬ 2003ꎬ64
结局的相关性研究 [ J] . 中华内分泌代谢杂志ꎬ 2014ꎬ30 ( 1) :3 ̄ (7) :851.
7. DOI: 10.3760 / cma.j.issn.1000 ̄6699.2014.01.002. [32] Farrell GCꎬ Chitturi Sꎬ Lau GKꎬ et al. Guidelines for the assessment
[17] Armstrong MJꎬ Adams LAꎬ Canbay Aꎬ et al. Extrahepatic complications and management of non ̄alcoholic fatty liver disease in the Asia ̄Pacific
of nonalcoholic fatty liver disease[ J] . Hepatologyꎬ 2014ꎬ59(3) :1174 ̄ region: executive summary[ J] . J Gastroenterol Hepatolꎬ 2007ꎬ22(6) :
1197. DOI: 10.1002 / hep.26717. 775 ̄777. DOI: 10.1111 / j.1440 ̄1746.2007.05002.x.
[18] Mantovani Aꎬ Zaza Gꎬ Byrne CDꎬ et al. Nonalcoholic fatty liver disease [33] Ali Rꎬ Cusi K. New diagnostic and treatment approaches in non ̄
increases risk of incident chronic kidney disease: A systematic review alcoholic fatty liver disease ( NAFLD) [ J] . Ann Medꎬ 2009ꎬ41( 4) :
and meta ̄analysis[ J] . Metabolismꎬ 2018ꎬ79:64 ̄76. DOI: 10. 1016 / 265 ̄278. DOI: 10.1080 / 07853890802552437.
j.metabol.2017.11.003. [34] Wong VWꎬ Chan WKꎬ Chitturi Sꎬ et al. Asia ̄Pacific Working Party on
[19] Xia MFꎬ Lin HDꎬ Yan HMꎬ et al. The association of liver fat content and Non ̄alcoholic Fatty Liver Disease guidelines 2017 ̄Part 1: Definitionꎬ
serum alanine aminotransferase with bone mineral density in middle ̄ risk factors and assessment[ J] . J Gastroenterol Hepatolꎬ 2018ꎬ33(1) :
aged and elderly Chinese men and postmenopausal women[ J] . J Transl 70 ̄85. DOI: 10.1111 / jgh.13857.
Medꎬ 2016ꎬ14:11. DOI: 10.1186 / s12967 ̄016 ̄0766 ̄3. [35] Szczepaniak LSꎬ Nurenberg Pꎬ Leonard Dꎬ et al. Magnetic resonance
[20] Wang Dꎬ Lin Hꎬ Xia Mꎬ et al. Vitamin D levels are inversely associated spectroscopy to measure hepatic triglyceride content: prevalence of
with liver fat content and risk of non ̄alcoholic fatty liver disease in a hepatic steatosis in the general population[ J] . Am J Physiol Endocrinol
Chinese middle ̄aged and elderly population: the Shanghai Changfeng Metabꎬ 2005ꎬ 288 ( 2) : E462 ̄E468. DOI: 10. 1152 / ajpendo. 00064.
Study[ J ] . PLoS Oneꎬ 2016ꎬ 11 ( 6 ) : e0157515. DOI: 10. 1371 / 2004.
journal.pone.0157515. [36] Xia MFꎬ Yan HMꎬ He WYꎬ et al. Standardized ultrasound hepatic /
[21] Lin Hꎬ Li Qꎬ Liu Xꎬ et al. Liver fat content is associated with elevated renal ratio and hepatic attenuation rate to quantify liver fat content: an
serum uric acid in the Chinese middle ̄aged and elderly populations: improvement method[ J] . Obesity ( Silver Spring) ꎬ 2012ꎬ20(2) :444 ̄
Shanghai Changfeng Study [ J ] . PLoS Oneꎬ 2015ꎬ 10 ( 10 ) : 452. DOI: 10.1038 / oby.2011.302.
e0140379. DOI: 10.1371 / journal.pone.0140379. [37] 曾静ꎬ 孙婉璐ꎬ 陈光榆ꎬ 等. FibroTouch 与 FibroScan 肝脏硬度和脂
[22] Adams LAꎬ Anstee QMꎬ Tilg Hꎬ et al. Non ̄alcoholic fatty liver disease 肪定量检测效能的比较[ J] . 中华肝脏病杂志ꎬ 2016ꎬ24(9) :652 ̄
and its relationship with cardiovascular disease and other extrahepatic 658. DOI: 10.3760 / cma.j.issn.1007 ̄3418.2016.09.004.
diseases[ J] . Gutꎬ 2017ꎬ 66 ( 6) : 1138 ̄1153. DOI: 10. 1136 / gutjnl ̄ [38] Singh Sꎬ Muir AJꎬ Dieterich DTꎬ et al. American Gastroenterological
2017 ̄313884. Association Institute Technical Review on the role of elastography in
[23] Rocha ALLꎬ Faria LCꎬ Guimaraes TCMꎬ et al. Non ̄alcoholic fatty liver chronic liver diseases [ J ] . Gastroenterologyꎬ 2017ꎬ 152 ( 6 ) : 1544 ̄
disease in women with polycystic ovary syndrome: systematic review and 1577. DOI: 10.1053 / j.gastro.2017.03.016.
meta ̄analysis[ J] . J Endocrinol Investꎬ 2017ꎬ 40 ( 12 ) : 1279 ̄1288. [39] Kleiner DEꎬ Brunt EMꎬ Van Natta Mꎬ et al. Design and validation of a
DOI: 10.1007 / s40618 ̄017 ̄0708 ̄9. histological scoring system for nonalcoholic fatty liver disease [ J ] .
[24] Li Yꎬ Xu Cꎬ Yu Cꎬ et al. Association of serum uric acid level with non ̄ Hepatologyꎬ 2005ꎬ41(6) :1313 ̄1321. DOI: 10.1002 / hep.20701.
alcoholic fatty liver disease: a cross ̄sectional study [ J ] . J Hepatolꎬ [40] Cusi K. Treatment of patients with type 2 diabetes and non ̄alcoholic fatty
2009ꎬ50(5) :1029 ̄1034. DOI: 10.1016 / j.jhep.2008.11.021. liver disease: current approaches and future directions [ J ] .
554 中华内分泌代谢杂志 2018 年 7 月第 34 卷第 7 期 Chin J Endocrinol Metabꎬ July 2018ꎬ Vol. 34ꎬ No. 7
Diabetologiaꎬ 2016ꎬ59 ( 6) :1112 ̄1120. DOI: 10. 1007 / s00125 ̄016 ̄ Framingham Heart Study [ J ] . Hepatologyꎬ 2010ꎬ 51 ( 6 ) : 1979 ̄
3952 ̄1. 1987. DOI: 10.1002 / hep.23593.
[41] Kleiner DEꎬ Brunt EM. Nonalcoholic fatty liver disease: pathologic [57] Rafiq Nꎬ Bai Cꎬ Fang Yꎬ et al. Long ̄term follow ̄up of patients with
patterns and biopsy evaluation in clinical research[ J] . Semin Liver Disꎬ nonalcoholic fatty liver[ J] . Clin Gastroenterol Hepatolꎬ 2009ꎬ7( 2) :
2012ꎬ32(1) :3 ̄13. DOI: 10.1055 / s ̄0032 ̄1306421. 234 ̄238. DOI: 10.1016 / j.cgh.2008.11.005.
[42] EASL ̄EASD ̄EASO Clinical Practice Guidelines for the management of [58] Wilson PWꎬ D'Agostino RBꎬ Levy Dꎬ et al. Prediction of coronary heart
non ̄alcoholic fatty liver disease [ J] . J Hepatolꎬ 2016ꎬ64 ( 6) :1388 ̄ disease using risk factor categories [ J] . Circulationꎬ 1998ꎬ97 ( 18) :
1402. DOI: 10.1016 / j.jhep.2015.11.004. 1837 ̄1847.
[43] Sanyal AJꎬ Chalasani Nꎬ Kowdley KVꎬ et al. Pioglitazoneꎬ vitamin Eꎬ [59] Zhang HJꎬ He Jꎬ Pan LLꎬ et al. Effects of moderate and vigorous
or placebo for nonalcoholic steatohepatitis[ J] . N Engl J Medꎬ 2010ꎬ exercise on nonalcoholic fatty liver disease: A randomized clinical trial
362(18) :1675 ̄1685. DOI: 10.1056 / NEJMoa0907929. [ J] . JAMA Intern Medꎬ 2016ꎬ176 ( 8) :1074 ̄1082. DOI: 10. 1001 /
[44] Angulo Pꎬ Hui JMꎬ Marchesini Gꎬ et al. The NAFLD fibrosis score: a jamainternmed.2016.3202.
noninvasive system that identifies liver fibrosis in patients with NAFLD [60] Zhang HJꎬ Pan LLꎬ Ma ZMꎬ et al. Long ̄term effect of exercise on
[ J] . Hepatologyꎬ 2007ꎬ45(4) :846 ̄854. DOI: 10.1002 / hep.21496. improving fatty liver and cardiovascular risk factors in obese adults: A 1 ̄
[45] Chalasani Nꎬ Younossi Zꎬ Lavine JEꎬ et al. The diagnosis and year follow ̄up study [ J] . Diabetes Obes Metabꎬ 2017ꎬ 19 ( 2) : 284 ̄
management of non ̄alcoholic fatty liver disease: Practice Guideline by 289. DOI: 10.1111 / dom.12809.
the American Association for the Study of Liver Diseasesꎬ American [61] Schugar RCꎬ Crawford PA. Low ̄carbohydrate ketogenic dietsꎬ glucose
College of Gastroenterologyꎬ and the American Gastroenterological homeostasisꎬ and nonalcoholic fatty liver disease [ J] . Curr Opin Clin
Association[ J ] . Hepatologyꎬ 2012ꎬ 142 ( 7 ) : 1592 ̄1609. DOI: 10. Nutr Metab Careꎬ 2012ꎬ 15 ( 4 ) : 374 ̄380. DOI: 10. 1097 / MCO.
1002 / hep.25762. 0b013e3283547157.
[46] Musso Gꎬ Gambino Rꎬ Cassader Mꎬ et al. Meta ̄analysis: natural history [62] Grattagliano Iꎬ Portincasa Pꎬ Palmieri VOꎬ et al. Managing
of non ̄alcoholic fatty liver disease ( NAFLD) and diagnostic accuracy of nonalcoholic fatty liver disease: recommendations for family physicians
non ̄invasive tests for liver disease severity [ J] . Ann Medꎬ 2011ꎬ 43 [ J] . Can Fam Physicianꎬ 2007ꎬ53(5) :857 ̄863.
(8) :617 ̄649. DOI: 10.3109 / 07853890.2010.518623. [63] Zeng MDꎬ Fan JGꎬ Lu LGꎬ et al. Guidelines for the diagnosis and
[47] Anstee QMꎬ Targher Gꎬ Day CP. Progression of NAFLD to diabetes treatment of nonalcoholic fatty liver diseases [ J] . J Dig Disꎬ 2008ꎬ9
mellitusꎬ cardiovascular disease or cirrhosis[ J] . Nat Rev Gastroenterol (2) :108 ̄112. DOI: 10.1111 / j.1751 ̄2980.2008.00331.x.
Hepatolꎬ 2013ꎬ10(6) :330 ̄344. DOI: 10.1038 / nrgastro.2013.41. [64] Han Yꎬ Shi JPꎬ Ma ALꎬ et al. Randomizedꎬ vitamin E ̄controlled trial of
[48] Kozlitina Jꎬ Smagris Eꎬ Stender Sꎬ et al. Exome ̄wide association study bicyclol plus metformin in non ̄alcoholic fatty liver disease patients with
identifies a TM6SF2 variant that confers susceptibility to nonalcoholic impaired fasting glucose [ J] . Clin Drug Investigꎬ 2014ꎬ 34 ( 1 ) : 1 ̄
fatty liver disease[ J] . Nat Genetꎬ 2014ꎬ46 ( 4) :352 ̄356. DOI: 10. 7. DOI: 10.1007 / s40261 ̄013 ̄0136 ̄3.
1038 / ng.2901. [65] Belfort Rꎬ Harrison SAꎬ Brown Kꎬ et al. A placebo ̄controlled trial of
[49] Xia MFꎬ Ling Yꎬ Bian Hꎬ et al. I148M variant of PNPLA3 increases the pioglitazone in subjects with nonalcoholic steatohepatitis[ J] . N Engl J
susceptibility to non ̄alcoholic fatty liver disease caused by obesity and Medꎬ 2006ꎬ355(22) :2297 ̄2307. DOI: 10.1056 / NEJMoa060326.
metabolic disorders[ J] . Aliment Pharmacol Therꎬ 2016ꎬ43( 5) :631 ̄ [66] Yan HMꎬ Xia MFꎬ Wang Yꎬ et al. Efficacy of berberine in patients with
642. DOI: 10.1111 / apt.13521. non ̄alcoholic fatty liver disease [ J ] . PLoS Oneꎬ 2015ꎬ 10 ( 8 ) :
[50] Li Yꎬ Xing Cꎬ Tian Zꎬ et al. Genetic variant I148M in PNPLA3 is e0134172. DOI: 10.1371 / journal.pone.0134172.
associated with the ultrasonography ̄determined steatosis degree in a [67] Musso Gꎬ Cassader Mꎬ Rosina Fꎬ et al. Impact of current treatments on
Chinese population [ J] . BMC Med Genetꎬ 2012ꎬ 13: 113. DOI: 10. liver diseaseꎬ glucose metabolism and cardiovascular risk in non ̄
1186 / 1471 ̄2350 ̄13 ̄113. alcoholic fatty liver disease ( NAFLD) : a systematic review and meta ̄
[51] Wang Xꎬ Liu Zꎬ Wang Kꎬ et al. Additive effects of the risk alleles of analysis of randomised trials [ J] . Diabetologiaꎬ 2012ꎬ 55 ( 4 ) : 885 ̄
PNPLA3 and TM6SF2 on non ̄alcoholic fatty liver disease ( NAFLD) in 904. DOI: 10.1007 / s00125 ̄011 ̄2446 ̄4.
a Chinese population[ J] . Front Genetꎬ 2016ꎬ7:140. DOI: 10.3389 / [68] Armstrong MJꎬ Gaunt Pꎬ Aithal GPꎬ et al. Liraglutide safety and
fgene.2016.00140. efficacy in patients with non ̄alcoholic steatohepatitis ( LEAN ) : a
[52] International Diabetes Federation. Criteria for metabolic syndrome. multicentreꎬ double ̄blindꎬ randomisedꎬ placebo ̄controlled phase 2
Cited2004 [ EB / OL ] . AvailablefromURL: http: / / www. idf. org / study [ J ] . Lancetꎬ 2016ꎬ 387 ( 10019 ) : 679 ̄690. DOI: 10. 1016 /
webdata / docs / IDF_metasyndmme ̄definitions.pdf. S0140 ̄6736(15)00803 ̄X.
[53] Vuppalanchi Rꎬ Chalasani N. Nonalcoholic fatty liver disease and [69] Neuschwander ̄Tetri BAꎬ Loomba Rꎬ Sanyal AJꎬ et al. Farnesoid X
nonalcoholic steatohepatitis: Selected practical issues in their evaluation nuclear receptor ligand obeticholic acid for non ̄cirrhoticꎬ non ̄alcoholic
and management [ J ] . Hepatologyꎬ 2009ꎬ 49 ( 1 ) : 306 ̄317. DOI: steatohepatitis ( FLINT ) : a multicentreꎬ randomisedꎬ placebo ̄
10.1002 / hep.22603. controlled trial [ J] . Lancetꎬ 2015ꎬ 385 ( 9972) : 956 ̄965. DOI: 10.
[54] Oni ETꎬ Agatston ASꎬ Blaha MJꎬ et al. A systematic review: burden 1016 / S0140 ̄6736(14)61933 ̄4.
and severity of subclinical cardiovascular disease among those with [70] Saez ̄Lara MJꎬ Robles ̄Sanchez Cꎬ Ruiz ̄Ojeda FJꎬ et al. Effects of
nonalcoholic fatty liverꎻ should we care? [ J] . Atherosclerosisꎬ 2013ꎬ probiotics and synbiotics on obesityꎬ insulin resistance syndromeꎬ type 2
230(2) :258 ̄267. DOI: 10.1016 / j.atherosclerosis.2013.07.052. diabetes and non ̄alcoholic fatty liver disease: a review of human clinical
[55] Targher Gꎬ Day CPꎬ Bonora E. Risk of cardiovascular disease in trials [ J ] . Int J Mol Sciꎬ 2016ꎬ 17 ( 6 ) : 928. DOI: 10. 3390 /
patients with nonalcoholic fatty liver disease[ J] . N Engl J Medꎬ 2010ꎬ ijms17060928.
363(14) :1341 ̄1350. DOI: 10.1056 / NEJMra0912063. ( 收稿日期:2018 ̄04 ̄24)
[56] Speliotes EKꎬ Massaro JMꎬ Hoffmann Uꎬ et al. Fatty liver is associated ( 本文编辑:周丽斌)
with dyslipidemia and dysglycemia independent of visceral fat: the